TEDCO’s Q1 Investments Top $2.7M to Fuel Innovation Across Maryland’s Diverse Startup Ecosystem

Published on : Published by : Annabel Baldy

TEDCO’s Q1 Investments Top $2.7M to Fuel Innovation Across Maryland’s Diverse Startup Ecosystem TEDCO deployed more than $2.7M of diverse investments in Maryland’s burgeoning technology and biotech sectors, driving innovation [….]

Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities

Published on : Published by : BioBuzz Media

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered an agreement to lease new laboratory and office space, commencing in June 2023, to complement the development of the Company’s lead drug candidates and accelerate broader diagnostic capabilities on predictive biomarkers. The new laboratory space, located in Gaithersburg, Maryland, is located within the Maryland Biotech Corridor.

REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

REGENXBIO Logo
Published on : Published by : BioBuzz Media

REGENXBIO Inc. (Nasdaq: RGNX) today announced results from a Phase II bridging study evaluating the pharmacodynamics, safety and efficacy of RGX-314, a potential one-time therapy delivered subretinally using cGMP material produced by the company’s NAVXpress™ bioreactor platform process. The data is being presented at the Angiogenesis, Exudation, and Degeneration 2023 Conference by Charles C. Wykoff, M.D., PhD., Director of Research at Retina Consultants of Texas; Chairman of Research, Retina Consultants of America; and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital.

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

Published on : Published by : BioBuzz Media

MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT), a leading commercial cell-engineering company providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc.,  a biotechnology company developing novel, off the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat a broad range of cancers, with a primary focus on solid tumors.

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

Published on : Published by : BioBuzz Media

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, today announced the signing of a strategic platform license (SPL).

MilliporeSigma invests $286M in new Montgomery County facility

Published on : Published by : BioBuzz Media

International biosciences company MilliporeSigma  is adding 500 new jobs to the Montgomery County region with its upcoming expansion project.
The company, known locally as BioReliance Corporation, is moving into a new 250,000 square-foot space at the Traville Gateway campus in Rockville, where it will retain at least 600 existing workers and add the new full-time positions. The company credits expanding its biosafety testing capacity in the Mid Atlantic due to Montgomery County’s ideal East Coast location and accessibility to Maryland’s highly trained and technical workforce.